# Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

> **NCT03002220** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 52 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** radium-223

## Key facts

- **NCT ID:** NCT03002220
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-21
- **Primary completion:** 2020-05-06
- **Final completion:** 2021-06-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002220, "Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03002220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*